Experimental therapy of human glioma by means of a genetically engineered virus mutant

Journal Article · Fri May 10 00:00:00 EDT 1991 · Science (Washington, D.C.); (United States)

DOI:https://doi.org/10.1126/science.1851332· OSTI ID:5827274

Martuza, R L; Malick, A; Markert, J M; Ruffner, K L; Coen, D M ^[1]

---

1. Harvard Medical School, Boston, MA (United States)

Malignant gliomas are the most common malignant brain tumors and are almost always fatal. A thymidine kinase-negative mutant of herpes simplex virus-1 (dlsptk) that is attenuated for neurovirulence was tested as a possible treatment for gliomas. In cell culture, dlsptk killed two long-term human glioma lines and three short-term human glioma cell populations. In nude mice with implanted subcutaneous and subrenal U87 human gliomas, intraneoplastic inoculation of dlsptk caused growth inhibition. In nude mice with intracranial U87 gliomas, intraneoplastic inoculation of dlsptk prolonged survival. Genetically engineered viruses such as dlsptk merit further evaluation as novel antineoplastic agents.

• OSTI ID: 5827274
• Journal Information: Science (Washington, D.C.); (United States), Vol. 252:5007; ISSN 0036-8075
• Country of Publication: United States
• Language: English

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
GLIOMAS
THERAPY
VIRUSES
GENETIC ENGINEERING
BRAIN
EXPERIMENTAL NEOPLASMS
HERPES SIMPLEX
MAN
MICE
MUTANTS
ANIMALS
BIOTECHNOLOGY
BODY
CENTRAL NERVOUS SYSTEM
DISEASES
INFECTIOUS DISEASES
MAMMALS
MICROORGANISMS
NEOPLASMS
NERVOUS SYSTEM
ORGANS
PARASITES
PRIMATES
RODENTS
SKIN DISEASES
VERTEBRATES
VIRAL DISEASES
550200* - Biochemistry